These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 20704848)

  • 1. Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells.
    Wei S; Kryczek I; Zou L; Curiel T; Cheng P; Zou W
    Discov Med; 2005 Oct; 5(29):489-92. PubMed ID: 20704848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
    Klippstein R; Pozo D
    Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells.
    Mascarell L; Lombardi V; Zimmer A; Louise A; Tourdot S; Van Overtvelt L; Moingeon P
    Clin Exp Allergy; 2009 Dec; 39(12):1910-9. PubMed ID: 19694757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of NK-cell function by mucins via antigen-presenting cells.
    Laskarin G; Redzovic A; Medancic SS; Rukavina D
    Med Hypotheses; 2010 Dec; 75(6):541-3. PubMed ID: 20702048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
    Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
    Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells in ovarian cancer: biology and therapeutic potential.
    Barnett B; Kryczek I; Cheng P; Zou W; Curiel TJ
    Am J Reprod Immunol; 2005 Dec; 54(6):369-77. PubMed ID: 16305662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
    Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
    Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ABCs of artificial antigen presentation.
    Kim JV; Latouche JB; Rivière I; Sadelain M
    Nat Biotechnol; 2004 Apr; 22(4):403-10. PubMed ID: 15060556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of antigen-presentation attenuators to augment vaccines.
    Evel-Kabler K; Chen SY
    Curr Opin Mol Ther; 2006 Feb; 8(1):24-30. PubMed ID: 16506522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A helper T cell clone produces an antigen-specific molecule (T-ABM) which functions in the induction of suppression.
    Green DR; Chue B; Zheng HG; Ferguson TA; Beaman KD; Flood PM
    J Mol Cell Immunol; 1987; 3(2):95-108. PubMed ID: 2978240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
    Foley R; Tozer R; Wan Y
    Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis.
    Chattergoon MA; Kim JJ; Yang JS; Robinson TM; Lee DJ; Dentchev T; Wilson DM; Ayyavoo V; Weiner DB
    Nat Biotechnol; 2000 Sep; 18(9):974-9. PubMed ID: 10973219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells from bench to bedside and back.
    Adema GJ
    Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.